BEIJING, Aug 16 (Xinhua): An inactivated Covid-19 vaccine candidate developed by China is safe and generates an immune response, according to data from clinical trials published in The Journal of the American Medical Association this week.
The research paper provided an interim analysis of the phase-1 and phase-2 clinical trials of an inactivated Covid-19 vaccine developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG), affiliated to Sinopharm, and the Wuhan Institute of Virology under the Chinese Academy of Sciences.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
